The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-10-29 DOI:10.1016/j.vaccine.2024.126482

Reuben McGregor , Aimee Paterson , Brittany Lavender , Caitlin Hooker , Chris Frampton , Kjesten Wiig , Graham Le Gros , James E. Ussher , Maia Brewerton , Nicole J. Moreland

{"title":"The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.","authors":"Reuben McGregor , Aimee Paterson , Brittany Lavender , Caitlin Hooker , Chris Frampton , Kjesten Wiig , Graham Le Gros , James E. Ussher , Maia Brewerton , Nicole J. Moreland","doi":"10.1016/j.vaccine.2024.126482","DOIUrl":null,"url":null,"abstract":"<div><div>The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020−2021) ensured the major vaccination campaign (Pfizer-BioNTech BNT162b2) was completed pre-omicron in an infection-naive population, providing a unique setting to explore the impact of omicron infection waves on vaccine responses. This study compared neutralising antibodies (NAb) to eight SARS-CoV-2 omicron sublineages 28-days and 11-months after a third dose. Participants (<em>n</em> = 219) were classified by antigen exposure in the intervening 10 months including additional vaccinations and/or infections. Both vaccination and infection boosted NAb levels to all sublineages. Antigenic maps showed infection had a major impact on NAb breadth, despite all participants being vaccinated with an ancestral-based vaccine.</div><div>While vaccination remains an important tool to boost immunity, the breadth of NAbs observed suggest that attempts to match booster specificity with current circulating variants may not always be necessary.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126482"},"PeriodicalIF":4.5000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24011642","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020−2021) ensured the major vaccination campaign (Pfizer-BioNTech BNT162b2) was completed pre-omicron in an infection-naive population, providing a unique setting to explore the impact of omicron infection waves on vaccine responses. This study compared neutralising antibodies (NAb) to eight SARS-CoV-2 omicron sublineages 28-days and 11-months after a third dose. Participants (n = 219) were classified by antigen exposure in the intervening 10 months including additional vaccinations and/or infections. Both vaccination and infection boosted NAb levels to all sublineages. Antigenic maps showed infection had a major impact on NAb breadth, despite all participants being vaccinated with an ancestral-based vaccine.

While vaccination remains an important tool to boost immunity, the breadth of NAbs observed suggest that attempts to match booster specificity with current circulating variants may not always be necessary.

查看原文本刊更多论文

2023 年新西兰成年人的 SARS-CoV-2 中和抗体概况：疫苗接种和感染的影响

SARS-CoV-2 omicron 亚系的相继占据主导地位给疫苗接种策略带来了增强剂抗原含量方面的挑战。新西兰的 COVID-19 消除战略（2020-2021 年）确保了主要疫苗接种活动（辉瑞-生物技术公司 BNT162b2）在非典型肺炎感染人群中完成，为探索非典型肺炎感染波对疫苗反应的影响提供了一个独特的环境。这项研究比较了 8 种 SARS-CoV-2 omicron 亚系的中和抗体（NAb），分别在第三次接种后 28 天和 11 个月。参与者（n = 219）按其间 10 个月的抗原接触情况分类，包括额外的疫苗接种和/或感染。接种疫苗和感染都会提高所有亚系的 NAb 水平。抗原图显示，尽管所有参与者都接种了基于祖先的疫苗，但感染对 NAb 的广度有重大影响。虽然接种疫苗仍是提高免疫力的重要工具，但观察到的 NAb 广度表明，尝试将增强特异性与当前流行的变异株相匹配可能并不总是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.